Is Vertex Stock Still a Good Buy?
Over the past ten years or so, Vertex Pharmaceuticals (NASDAQ:…
Buy
53
PRLB Quote, Financials, Valuation and Earnings
Last price:
$34.55
Seasonality move
:
12.11%
Day range:
$34.61 - $35.45
52-week range:
$25.76 - $46.73
Dividend yield:
0%
P/E ratio:
54.48x
P/S ratio:
1.78x
P/B ratio:
1.26x
Volume:
100.5K
Avg. volume:
226.5K
1-year change:
12.91%
Market cap:
$841.7M
Revenue:
$500.9M
EPS (TTM):
$0.65
Analysts' Opinion
-
Consensus RatingProto Labs has received a consensus rating of Hold. The company's average rating is a Hold based on 2 Buy ratings, 3 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $44.33, Proto Labs has an estimated upside of 25.2% from its current price of $35.41.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $38.00 representing 100% downside risk from its current price of $35.41.
Fair Value
-
According to the consensus of 5 analysts, Proto Labs has 25.2% upside to fair value with a price target of $44.33 per share.
PRLB vs. S&P 500
-
Over the past 5 trading days, Proto Labs has overperformed the S&P 500 by 4.88% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Proto Labs does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Proto Labs revenues have been falling on a year-over-year basis for 2 quarters in a row. In the most recent quarter Proto Labs reported revenues of $121.8M.
Earnings Growth
-
Proto Labs earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Proto Labs reported earnings per share of -$0.02.
Enterprise value:
738.6M
EV / Invested capital:
--
Price / LTM sales:
1.78x
EV / EBIT:
28.97x
EV / Revenue:
1.47x
PEG ratio (5yr expected):
--
EV / Free cash flow:
10.76x
Price / Operating cash flow:
13.01x
Enterprise value / EBITDA:
12.05x
Gross Profit (TTM):
$223.2M
Return On Assets:
2.19%
Net Income Margin (TTM):
3.31%
Return On Equity:
2.43%
Return On Invested Capital:
2.43%
Operating Margin:
3.36%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | $488.4M | $503.9M | $500.9M | $125M | $121.8M | |
| Gross Profit | $215.5M | $222M | $223.2M | $55.8M | $52M | |
| Operating Income | $26.9M | $28.4M | $25.5M | $8.4M | $4.1M | |
| EBITDA | $66.4M | $65.9M | $61.3M | $17.7M | $12.9M | |
| Diluted EPS | -$3.82 | $0.67 | $0.65 | $0.27 | -$0.02 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $242M | $183.5M | $186.6M | $200.7M | $194.9M | |
| Total Assets | $744.2M | $928.6M | $802.2M | $772.4M | $743.5M | |
| Current Liabilities | $50.3M | $54.9M | $71.6M | $49.7M | $53.3M | |
| Total Liabilities | $99.8M | $100.1M | $104.5M | $77.1M | $73.4M | |
| Total Equity | $644.4M | $828.5M | $697.6M | $695.3M | $670.2M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $62.1M | $73.3M | $77.8M | $17.2M | $17.3M | |
| Cash From Investing | -$43.1M | -$4.6M | -$13.6M | -$14.4M | -$2.9M | |
| Cash From Financing | -$27.9M | -$41.9M | -$58.6M | -$3.1M | -$12.5M | |
| Free Cash Flow | $40.4M | $45.2M | $68.7M | -$953K | $16.5M | |
PRLB
Sector
Market Cap
$841.7M
$588.9M
Price % of 52-Week High
75.78%
72.6%
Dividend Yield
0%
0%
Shareholder Yield
6.15%
2.44%
1-Year Price Total Return
12.92%
-8.43%
Beta (5-Year)
1.524
0.764
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$34.23
200-day SMA
Buy
Level
$35.19
Bollinger Bands (100)
Sell
Level
35.36 - 42.34
Chaikin Money Flow
Buy
Level
2.8M
20-day SMA
Buy
Level
$33.92
Relative Strength Index (RSI14)
Buy
Level
52.68
ADX Line
Buy
Level
16.7
Williams %R
Sell
Level
-8.6957
50-day SMA
Sell
Level
$36.69
MACD (12, 26)
Sell
Level
-0.40
25-day Aroon Oscillator
Sell
Level
-32
On Balance Volume
Sell
Level
-1.2M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (9.2208)
Buy
CA Score
(Annual)
Level (1.7859)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (7)
Buy
Ohlson Score
Level (-3.4286)
Buy
Piotroski F Score
(Annual)
Level (7)
Buy
Quality Ratio Score
Level (5)
Sell
Fundamental Score
Level (5)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Proto Labs Inc is an on-demand manufacturer of custom parts for prototyping and short-run production. The company offers developers and engineers quick-turn production services to reduce the time to market. Proto Labs uses injection molding, computer numerical control machining, and 3-D printing to manufacture custom parts for its clients. The company services clients' needs for prototype solutions, parts for testing procedures, bridge production capabilities during disruptions in manufacturing processes, limited-quantity requests, and end-of-life production support. Geographically, a majority of the company's revenue is derived from the United States and the rest from Europe.
Stock Forecast FAQ
In the current month, PRLB has received 2 Buy ratings 3 Hold ratings, and 0 Sell ratings. The PRLB average analyst price target in the past 3 months is $44.33.
-
Where Will Proto Labs Stock Be In 1 Year?
According to analysts, the consensus estimate is that Proto Labs share price will rise to $44.33 per share over the next 12 months.
-
What Do Analysts Say About Proto Labs?
Analysts are divided on their view about Proto Labs share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Proto Labs is a Sell and believe this share price will drop from its current level to $38.00.
-
What Is Proto Labs's Price Target?
The price target for Proto Labs over the next 1-year time period is forecast to be $44.33 according to 5 Wall Street analysts, 2 of them rate the stock a Buy, 0 rate the stock a Sell, and 3 analysts rate the stock a Hold.
-
Is PRLB A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Proto Labs is a Hold. 3 of 5 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of PRLB?
You can purchase shares of Proto Labs via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Proto Labs shares.
-
What Is The Proto Labs Share Price Today?
Proto Labs was last trading at $34.55 per share. This represents the most recent stock quote for Proto Labs. Yesterday, Proto Labs closed at $35.41 per share.
-
How To Buy Proto Labs Stock Online?
In order to purchase Proto Labs stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Okta Stock Finally Gaining Investor Confidence?
Given how digital transformation has proliferated, cyberattacks have also been…
Is The Trade Desk the Best Advertising Stock Now?
The worldly backdrop is now shrouded in heavy uncertainty and…
Stock Ideas
Buy
59
Is AAPL Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 35x
Buy
58
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Buy
55
Is NVDA Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 37x
Alerts
Buy
85
HIMS alert for Apr 30
Hims & Hers Health [HIMS] is down 5.99% over the past day.
Buy
54
EAT alert for Apr 30
Brinker International [EAT] is down 2% over the past day.
Sell
16
NSP alert for Apr 30
Insperity [NSP] is down 4.25% over the past day.
